Drug discovery in rare indications: opportunities and challenges

被引：3

作者：

Richon, Victoria M. ^{[1
]}

机构：

[1] Sanofi Oncol, Cambridge, MA 02139 USA

来源：

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2013年

关键词：

MLL TRANSLOCATIONS; H3K79; METHYLATION; CHROMATIN; LEUKEMIA; POTENT; DOT1L; METHYLTRANSFERASE; INHIBITION; ELONGATION; GENE;

D O I：

10.1182/asheducation-2013.1.19

中图分类号：

G40 [教育学];

学科分类号：

040101 ; 120403 ;

摘要：

Over the past decade, the number of new therapies developed for the treatment of rare diseases continues to increase. The most rapid growth has been in the development of new drugs for oncology indications. One focus in drug discovery for oncology indications is the development of targeted therapies for select patient subgroups characterized by genetic alterations. The identification of these patient subgroups has increased in the past decade and has resulted in a corresponding increase in the development of new drugs for genetically defined patient subgroups. As an example of the development of new therapeutics for rare indications, I describe here the drug discovery efforts leading to the development of DOT1L inhibitors for the treatment of MLL-rearranged leukemia.

引用

页码：19 / 23

页数：5

共 23 条

[1] DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis [J].

Anh Tram Nguyen ;

Taranova, Olena ;

He, Jin ;

Zhang, Yi .

BLOOD, 2011, 117 (25) :6912-6922

[2] MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia [J].

Armstrong, SA ;

Staunton, JE ;

Silverman, LB ;

Pieters, R ;

de Boer, ML ;

Minden, MD ;

Sallan, SE ;

Lander, ES ;

Golub, TR ;

Korsmeyer, SJ .

NATURE GENETICS, 2002, 30 (01) :41-47

[3] Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L [J].

Basavapathruni, Aravind ;

Jin, Lei ;

Daigle, Scott R. ;

Majer, Christina R. A. ;

Therkelsen, Carly A. ;

Wigle, Tim J. ;

Kuntz, Kevin W. ;

Chesworth, Richard ;

Pollock, Roy M. ;

Scott, Margaret P. ;

Moyer, Mikel P. ;

Richon, Victoria M. ;

Copeland, Robert A. ;

Olhava, Edward J. .

CHEMICAL BIOLOGY & DRUG DESIGN, 2012, 80 (06) :971-980

[4] MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L [J].

Bernt, Kathrin M. ;

Zhu, Nan ;

Sinha, Amit U. ;

Vempati, Sridhar ;

Faber, Joerg ;

Krivtsov, Andrei V. ;

Feng, Zhaohui ;

Punt, Natalie ;

Daigle, Amanda ;

Bullinger, Lars ;

Pollock, Roy M. ;

Richon, Victoria M. ;

Kung, Andrew L. ;

Armstrong, Scott A. .

CANCER CELL, 2011, 20 (01) :66-78

[5] Cancer genomics: from discovery science to personalized medicine [J].

Chin, Lynda ;

Andersen, Jannik N. ;

Futreal, P. Andrew .

NATURE MEDICINE, 2011, 17 (03) :297-303

[6] Potent inhibition of DOT1L as treatment of MLL-fusion leukemia [J].

Daigle, Scott R. ;

Olhava, Edward J. ;

Therkelsen, Carly A. ;

Basavapathruni, Aravind ;

Jin, Lei ;

Boriack-Sjodin, P. Ann ;

Allain, Christina J. ;

Klaus, Christine R. ;

Raimondi, Alejandra ;

Scott, Margaret Porter ;

Waters, Nigel J. ;

Chesworth, Richard ;

Moyer, Mikel P. ;

Copeland, Robert A. ;

Richon, Victoria M. ;

Pollock, Roy M. .

BLOOD, 2013, 122 (06) :1017-1025

[7] Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor [J].

Daigle, Scott R. ;

Olhava, Edward J. ;

Therkelsen, Carly A. ;

Majer, Christina R. ;

Sneeringer, Christopher J. ;

Song, Jeffrey ;

Johnston, L. Danielle ;

Scott, Margaret Porter ;

Smith, Jesse J. ;

Xiao, Yonghong ;

Jin, Lei ;

Kuntz, Kevin W. ;

Chesworth, Richard ;

Moyer, Mike P. ;

Bernt, Kathrin M. ;

Tseng, Jen-Chieh ;

Kung, Andrew L. ;

Armstrong, Scott A. ;

Copeland, Robert A. ;

Richon, Victoria M. ;

Pollock, Roy M. .

CANCER CELL, 2011, 20 (01) :53-65

[8] Chromatin modifications as therapeutic targets in MLL-rearranged leukemia [J].

Deshpande, Aniruddha J. ;

Bradner, James ;

Armstrong, Scott A. .

TRENDS IN IMMUNOLOGY, 2012, 33 (11) :563-570

[9] Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain [J].

Feng, Q ;

Wang, HB ;

Ng, HH ;

Erdjument-Bromage, H ;

Tempst, P ;

Struhl, K ;

Zhang, Y .

CURRENT BIOLOGY, 2002, 12 (12) :1052-1058

[10] Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia [J].

Guenther, Matthew G. ;

Lawton, Lee N. ;

Rozovskaia, Tatiana ;

Frampton, Garrett M. ;

Levine, Stuart S. ;

Volkert, Thomas L. ;

Croce, Carlo M. ;

Nakamura, Tatsuya ;

Canaani, Eli ;

Young, Richard A. .

GENES & DEVELOPMENT, 2008, 22 (24) :3403-3408

← 1 2 3 →